nach oben

Erschienen in:

06.06.2020 | Original Article

Expression of BAFF and BAFF receptors in primary Sjögren’s syndrome patients with ectopic germinal center-like structures

verfasst von: F. J. Carrillo-Ballesteros, C. A. Palafox-Sánchez, R. A. Franco-Topete, J. F. Muñoz-Valle, G. Orozco-Barocio, G. E. Martínez-Bonilla, C. E. Gómez-López, M. Marín-Rosales, E. F. López-Villalobos, S. Luquin, A. Castañeda-Chávez, Edith Oregon-Romero

Erschienen in: Clinical and Experimental Medicine | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

B cell-activating factor (BAFF) is an essential cytokine in primary Sjögren’s syndrome (pSS) physiopathology. It has been reported that pSS patients develop germinal center-like (GC-like) structures in their minor salivary glands (MSGs). BAFF, BAFF-R, TACI, and BCMA expression was analyzed in MSGs from 29 subjects (nonspecific chronic sialadenitis and focal lymphocytic sialadenitis with the presence [pSS-GC(+)] or absence [pSS-GC(−)] of GC-like structures). Twenty-four percent of patients showed ectopic GC-like structures and a high focus score [p < 0.001 vs pSS-GC(−)]. BAFF serum levels (sBAFF) were high in pSS patients (p = 0.025 vs healthy subjects). However, the pSS-GC(−) group showed higher sBAFF levels than pSS-GC(+) patients. BAFF and BAFF-R glandular expression levels were higher in pSS-GC(+) patients, without significant differences compared to pSS-GC(−) patients. Soluble levels of BAFF correlated with anti-La/SSB antibodies and disease duration. Our results showed that BAFF could contribute to focal lymphocytic infiltration. The role of BAFF-binding receptors in MSGs is proposed as a mechanism for the possible establishment of ectopic GC-like structures and disease progression in some patients. In conclusion, this study supports previous evidence that considers the active BAFF system role in the pathogenesis of pSS and the need for strong biomarkers in this disease.

Goules AV, Kapsogeorgou EK, Tzioufas AG. Insight into pathogenesis of Sjögren’s syndrome: dissection on autoimmune infiltrates and epithelial cells. Clin Immunol Orlando Fla. 2017;182:30–40.CrossRef

Brito-Zerón P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, et al. Sjögren syndrome. Nat Rev Dis Primer. 2016;2:16047.CrossRef

Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjögren’s syndrome. J Autoimmun. 2010;34:400–7.PubMedCrossRef

Mingueneau M, Boudaoud S, Haskett S, Reynolds TL, Nocturne G, Norton E, et al. Cytometry by time-of-flight immunophenotyping identifies a blood Sjögren’s signature correlating with disease activity and glandular inflammation. J Allergy Clin Immunol. 2016;137(1809–1821):e12.

Muskardin TLW, Niewold TB. Type I interferon in rheumatic diseases. Nat Rev Rheumatol. 2018;14:214–28.PubMedPubMedCentralCrossRef

Johnsen SJ, Berget E, Jonsson MV, Helgeland L, Omdal R, Jonsson R. Evaluation of germinal center-like structures and B cell clonality in patients with primary Sjögren syndrome with and without lymphoma. J Rheumatol. 2014;41:2214–22.PubMedCrossRef

Sène D, Ismael S, Forien M, Charlotte F, Kaci R, Cacoub P, et al. Ectopic germinal centre-like structures in minor salivary gland biopsy predict lymphoma occurrence in patients with primary Sjögren syndrome. Arthritis Rheumatol. 2018;70:1481–88.PubMedCrossRef

Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013;24:203–15.PubMedPubMedCentralCrossRef

Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol. 2006;18:263–75.PubMedCrossRef

10.

Wei F, Chang Y, Wei W. The role of BAFF in the progression of rheumatoid arthritis. Cytokine. 2015;76:537–44.PubMedCrossRef

11.

Salazar-Camarena DC, Ortiz-Lazareno PC, Cruz A, Oregon-Romero E, Machado-Contreras JR, Muñoz-Valle JF, et al. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus. Lupus. 2016;25:582–92.PubMedCrossRef

12.

Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10:365–73.PubMedCrossRef

13.

Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren’s syndrome. Ann Rheum Dis. 2003;62:168–71.PubMedPubMedCentralCrossRef

14.

Lee SJ, Oh HJ, Choi BY, Jang YJ, Lee JY, Park JK, et al. Serum 25-hydroxyvitamin D3 and BAFF levels are associated with disease activity in primary Sjogren’s syndrome. J Immunol Res. 2016;2016:5781070.PubMedPubMedCentral

15.

Lahiri A, Varin M-M, Le Pottier L, Pochard P, Bendaoud B, Youinou P, et al. Specific forms of BAFF favor BAFF receptor-mediated epithelial cell survival. J Autoimmun. 2014;51:30–7.PubMedCrossRef

16.

Lavie F, Miceli-Richard C, Quillard J, Roux S, Leclerc P, Mariette X. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren’s syndrome. J Pathol. 2004;202:496–502.PubMedCrossRef

17.

He J, Jin Y, Zhang X, Zhou Y, Li R, Dai Y, et al. Characteristics of germinal center-like structures in patients with Sjögren’s syndrome. Int J Rheum Dis. 2017;20:245–51.PubMedCrossRef

18.

Fayyaz A, Kurien BT, Scofield RH. Autoantibodies in Sjögren’s syndrome. Rheum Dis Clin North Am. 2016;42:419–34.PubMedPubMedCentralCrossRef

19.

Lee K-E, Kang J-H, Yim Y-R, Kim J-E, Lee J-W, Wen L, et al. The significance of ectopic germinal centers in the minor salivary gland of patients with Sjögren’s syndrome. J Korean Med Sci. 2016;31:190–5.PubMedPubMedCentralCrossRef

20.

Maślińska M, Kontny E, Kwiatkowska B. The relationship between the presence of autoantibodies, indicators of local and systemic inflammation, the serum concentration of B-cell activating factor (BAFF) and the intensity of salivary gland infiltration in patients with primary Sjögren’s syndrome—a preliminary study. Reumatologia. 2015;53:321–7.PubMedCrossRef

21.

Nocturne G, Mariette X. B cells in the pathogenesis of primary Sjögren syndrome. Nat Rev Rheumatol. 2018;14:133–45.PubMedCrossRef

22.

Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren’s syndrome. J Clin Immunol. 2005;25:189–201.PubMedCrossRef

23.

Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76:9–16.PubMedCrossRef

24.

Vitali C, Palombi G, Baldini C, Benucci M, Bombardieri S, Covelli M, et al. Sjögren’s syndrome disease damage index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren’s syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum. 2007;56:2223–31.PubMedCrossRef

25.

Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al. EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis. 2010;69:1103–9.PubMedCrossRef

26.

Chatterjee S, Malhotra R, Varghese F, Bukhari AB, Patil A, Budrukkar A, et al. Quantitative immunohistochemical analysis reveals association between sodium iodide symporter and estrogen receptor expression in breast cancer. PLoS ONE. 2013;8:e54055.PubMedPubMedCentralCrossRef

27.

Fisher BA, Brown RM, Bowman SJ, Barone F. A review of salivary gland histopathology in primary Sjögren’s syndrome with a focus on its potential as a clinical trials biomarker. Ann Rheum Dis. 2015;74:1645–50.PubMedCrossRef

28.

Wicheta S, Van der Groen T, Faquin WC, August M. Minor salivary gland biopsy—an important contributor to the diagnosis of Sjögren syndrome. J Oral Maxillofac Surg. 2017;75:2573–8.PubMedCrossRef

29.

Jonsson MV, Skarstein K, Jonsson R, Brun JG. Serological implications of germinal center-like structures in primary Sjögren’s syndrome. J Rheumatol. 2007;34:2044–9.PubMed

30.

Ding J, Zhang W, Haskett S, Pellerin A, Xu S, Petersen B, et al. BAFF overexpression increases lymphocytic infiltration in Sjögren’s target tissue, but only inefficiently promotes ectopic B-cell differentiation. Clin Immunol Orlando Fla. 2016;169:69–79.CrossRef

31.

Naradikian MS, Perate AR, Cancro MP. BAFF receptors and ligands create independent homeostatic niches for B cell subsets. Curr Opin Immunol. 2015;34:126–9.PubMedCrossRef

32.

Szodoray P, Alex P, Jonsson MV, Knowlton N, Dozmorov I, Nakken B, et al. Distinct profiles of Sjögren’s syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol Orlando Fla. 2005;117:168–76.CrossRef

33.

Sharma A, Kiripolsky J, Klimatcheva E, Howell A, Fereidouni F, Levenson R, et al. Early BAFF receptor blockade mitigates murine Sjögren’s syndrome: concomitant targeting of CXCL13 and the BAFF receptor prevents salivary hypofunction. Clin Immunol. 2016;164:85–94.PubMedPubMedCentralCrossRef

34.

Carubbi F, Cipriani P, Di Benedetto P, Ruscitti P, Alunno A, Gerli R, et al. Persistence of focal lymphocytic sialadenitis in patients with primary Sjögren’s syndrome treated with rituximab: a possible role for glandular BAFF. Clin Exp Rheumatol. 2016;34:1123–4.PubMed

35.

Navarro-Mendoza EP, Aguirre-Valencia D, Posso-Osorio I, Correa-Forero SV, Torres-Cutiva D-F, Loaiza D, et al. Cytokine markers of B lymphocytes in minor salivary gland infiltrates in Sjögren’s syndrome. Autoimmun Rev. 2018;17:709–14.PubMedCrossRef

36.

Baldini C, Ferro F, Elefante E, Bombardieri S. Biomarkers for Sjögren’s syndrome. Biomark Med. 2018;12:275–86.PubMedCrossRef

37.

Sisto M, Lorusso L, Lisi S. TLR2 signals via NF-κB to drive IL-15 production in salivary gland epithelial cells derived from patients with primary Sjögren’s syndrome. Clin Exp Med. 2017;17:341–50.PubMedCrossRef

38.

Sisto M, Lisi S, D’Amore M, Lofrumento DD. The metalloproteinase ADAM17 and the epidermal growth factor receptor (EGFR) signaling drive the inflammatory epithelial response in Sjögren’s syndrome. Clin Exp Med. 2015;15:215–25.PubMedCrossRef

39.

Ng LG, Sutherland APR, Newton R, Qian F, Cachero TG, Scott ML, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol. 2004;173:807–17.PubMedCrossRef

40.

Haacke EA, van der Vegt B, Meiners PM, Vissink A, Spijkervet FKL, Bootsma H, et al. Abatacept treatment of patients with primary Sjögren’s syndrome results in a decrease of germinal centres in salivary gland tissue. Clin Exp Rheumatol. 2017;35:317–20.PubMed

41.

Hu S, Wang R, Zhang M, Liu K, Tao J, Tai Y, et al. BAFF promotes T cell activation through the BAFF-BAFF-R-PI3K-Akt signaling pathway. Biomed Pharmacother. 2019;114:108796.PubMedCrossRef

42.

Nezos A, Papageorgiou A, Fragoulis G, Ioakeimidis D, Koutsilieris M, Tzioufas AG, et al. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren’s syndrome. J Autoimmun. 2014;51:89–988.PubMedCrossRef

43.

Papageorgiou A, Mavragani CP, Nezos A, Zintzaras E, Quartuccio L, De Vita S, et al. A BAFF receptor His159Tyr mutation in Sjögren’s syndrome-related lymphoproliferation. Arthritis Rheumatol Hoboken NJ. 2015;67:2732–41.CrossRef

44.

Thompson N, Isenberg DA, Jury EC, Ciurtin C. Exploring BAFF: its expression, receptors and contribution to the immunopathogenesis of Sjögren’s syndrome. Rheumatol Oxf Engl. 2016;55:1548–55.CrossRef

45.

Pontarini E, Fabris M, Quartuccio L, Cappeletti M, Calcaterra F, Roberto A, et al. Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren’s syndrome. Rheumatol Oxf Engl. 2015;54:1429–34.CrossRef

46.

McWilliams EM, Lucas CR, Chen T, Harrington BK, Wasmuth R, Campbell A, et al. Anti–BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. Blood Adv. 2019;3:447–60.PubMedPubMedCentralCrossRef

47.

Dörner T, Posch MG, Li Y, Petricoul O, Cabanski M, Milojevic JM, et al. Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Ann Rheum Dis. 2019;78:641–7.PubMedCrossRef

48.

Ou X, Xu S, Lam K-P. Deficiency in TNFRSF13B (TACI) expands T-follicular helper and germinal center B cells via increased ICOS-ligand expression but impairs plasma cell survival. Proc Natl Acad Sci. 2012;109:15401–6.PubMedCrossRefPubMedCentral

49.

Arkatkar T, Jacobs HM, Du SW, Li Q-Z, Hudkins KL, Alpers CE, et al. TACI deletion protects against progressive murine lupus nephritis induced by BAFF overexpression. Kidney Int. 2018;94:728–40.PubMedPubMedCentralCrossRef

50.

Romberg N, Chamberlain N, Saadoun D, Gentile M, Kinnunen T, Ng YS, et al. CVID-associated TACI mutations affect autoreactive B cell selection and activation. J Clin Invest. 2013;123:4283–93.PubMedPubMedCentralCrossRef

51.

Coquery CM, Erickson LD. Regulatory roles of the tumor necrosis factor receptor BCMA. Crit Rev Immunol. 2012;32:287–305.PubMedPubMedCentralCrossRef

52.

Jiang C, Loo WM, Greenley EJ, Tung KS, Erickson LD. B cell maturation antigen deficiency exacerbates lymphoproliferation and autoimmunity in murine lupus. J Immunol Baltim Md. 1950;2011(186):6136–47.

53.

Coquery CM, Loo WM, Wade NS, Bederman AG, Tung KS, Lewis JE, et al. BAFF regulates follicular helper T cells and affects their accumulation and interferon-γ production in autoimmunity: BAFF regulates follicular helper T cells. Arthritis Rheumatol. 2015;67:773–84.PubMedPubMedCentralCrossRef

54.

Shaker OG, Tawfic SO, El-Tawdy AM, El-Komy MHM, El Menyawi M, Heikal AA. Expression of TNF-α, APRIL and BCMA in Behcet’s disease. J Immunol Res. 2014;2014:380405.PubMedPubMedCentralCrossRef

55.

Chang Y, Jia X, Sun X, Xu S, Wu Y, Zhang L, et al. APRIL promotes proliferation, secretion and invasion of fibroblast-like synoviocyte from rats with adjuvant induced arthritis. Mol Immunol. 2015;64:90–8.PubMedCrossRef

56.

Eilertsen GØ, Nossent JC. APRIL levels strongly correlate with IL-17 in systemic lupus erythematosus. Lupus. 2014;23:1383–91.PubMedCrossRef

57.

Lombardi T, Moll S, Youinou P, Pers J-O, Tzankov A, Gabay C, et al. Absence of up-regulation for a proliferation-inducing ligand in Sjögren’s sialadenitis lesions. Rheumatol Oxf Engl. 2011;50:1211–5.CrossRef

58.

Vosters JL, Roescher N, Polling EJ, Illei GG, Tak PP. The expression of APRIL in Sjogren’s syndrome: aberrant expression of APRIL in the salivary gland. Rheumatol Oxf Engl. 2012;51:1557–622.CrossRef

59.

Fauchais AL, Martel C, Gondran G, Lambert M, Launay D, Jauberteau MO, et al. Immunological profile in primary Sjögren syndrome: clinical significance, prognosis and long-term evolution to other auto-immune disease. Autoimmun Rev. 2010;9:595–9.PubMedCrossRef

60.

Friebus-Kardash J, Branco L, Ribi C, Chizzolini C, Huynh-Do U, Dubler D, et al. Immune complexes containing serum B-cell activating factor and immunoglobulin G correlate with disease activity in systemic lupus erythematosus. Nephrol Dial Transplant. 2018;33:54–64.PubMedCrossRef

Titel: Expression of BAFF and BAFF receptors in primary Sjögren’s syndrome patients with ectopic germinal center-like structures
verfasst von: F. J. Carrillo-Ballesteros
C. A. Palafox-Sánchez
R. A. Franco-Topete
J. F. Muñoz-Valle
G. Orozco-Barocio
G. E. Martínez-Bonilla
C. E. Gómez-López
M. Marín-Rosales
E. F. López-Villalobos
S. Luquin
A. Castañeda-Chávez
Edith Oregon-Romero
Publikationsdatum: 06.06.2020
Verlag: Springer International Publishing
Erschienen in: Clinical and Experimental Medicine / Ausgabe 4/2020
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI: https://doi.org/10.1007/s10238-020-00637-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer

Organ-specific manifestations of COVID-19 infection

The risk of cardiovascular complications in inflammatory bowel disease

Association between complement 4 copy number variation and systemic lupus erythematosus: a meta-analysis

IGFBP3 as an indicator of lymph node metastasis and unfavorable prognosis for papillary thyroid carcinoma